1.1
Etanercept, infliximab and adalimumab are recommended for the treatment of adults with active and progressive psoriatic arthritis when the following criteria are met:
-
the person has peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and
-
the psoriatic arthritis has not responded to adequate trials of at least 2 standard disease-modifying antirheumatic drugs (DMARDs), administered either individually or in combination.